Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier J Wouters

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
JAMA Internal Medicine|March 4, 2020
Lobbying Expenditures and Campaign Contributions by the Pharmaceutical and Health Product Industry in the United States, 1999-2018Olivier J Wouters
International Journal of Health Policy and Management|October 16, 2022
The Challenges of Regulating Artificial Intelligence in Healthcare Comment on "Clinical Decision Support and New Regulatory Frameworks for Medical Devices: Are We Ready for It? - A Viewpoint Paper"Martin McKee, Olivier J Wouters
Health Affairs (Project Hope)|October 7, 2024
Low- And Middle-Income Countries Experienced Delays Accessing New Essential Medicines, 1982-2024Olivier J Wouters, Jouni Kuha
Bulletin of the World Health Organization|October 20, 2015
Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reformOlivier J Wouters, Panos G Kanavos
BMC Health Services Research|April 1, 2017
A comparison of generic drug prices in seven European countries: a methodological analysisOlivier J Wouters, Panos G Kanavos
JAMA|March 4, 2020
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018Olivier J Wouters, Martin McKee, Jeroen Luyten
Heart (British Cardiac Society)|September 24, 2015
QALYs in cost-effectiveness analysis: an overview for cardiologistsOlivier J Wouters, Huseyin Naci, Nilesh J Samani
The Milbank Quarterly|September 13, 2017
Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and SpendingOlivier J Wouters, Panos G Kanavos, Martin McKEE
JAMA Health Forum|August 15, 2025
Prices and Affordability of Essential Medicines in 72 Low-, Middle-, and High-Income MarketsOlivier J Wouters, Cyprien Denolle, Jinru Wei, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 8, 2024
Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014Olivier J Wouters, Aaron S Kesselheim, Jouni Kuha, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
JAMA Internal Medicine|March 4, 2020
Lobbying Expenditures and Campaign Contributions by the Pharmaceutical and Health Product Industry in the United States, 1999-2018Olivier J Wouters
International Journal of Health Policy and Management|October 16, 2022
The Challenges of Regulating Artificial Intelligence in Healthcare Comment on "Clinical Decision Support and New Regulatory Frameworks for Medical Devices: Are We Ready for It? - A Viewpoint Paper"Martin McKee, Olivier J Wouters
Health Affairs (Project Hope)|October 7, 2024
Low- And Middle-Income Countries Experienced Delays Accessing New Essential Medicines, 1982-2024Olivier J Wouters, Jouni Kuha
Bulletin of the World Health Organization|October 20, 2015
Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reformOlivier J Wouters, Panos G Kanavos
BMC Health Services Research|April 1, 2017
A comparison of generic drug prices in seven European countries: a methodological analysisOlivier J Wouters, Panos G Kanavos
JAMA|March 4, 2020
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018Olivier J Wouters, Martin McKee, Jeroen Luyten
Heart (British Cardiac Society)|September 24, 2015
QALYs in cost-effectiveness analysis: an overview for cardiologistsOlivier J Wouters, Huseyin Naci, Nilesh J Samani
The Milbank Quarterly|September 13, 2017
Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and SpendingOlivier J Wouters, Panos G Kanavos, Martin McKEE
JAMA Health Forum|August 15, 2025
Prices and Affordability of Essential Medicines in 72 Low-, Middle-, and High-Income MarketsOlivier J Wouters, Cyprien Denolle, Jinru Wei, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 8, 2024
Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014Olivier J Wouters, Aaron S Kesselheim, Jouni Kuha, et al.
Pageof 3